International Study Finds New Drugs Combination to Cut Deaths from Diabetes

The largest-ever study of treatments for diabetes has shown that a combination of two blood pressure-lowering drugs reduces the risk of death, heart attack and kidney disease in diabetes sufferers. The "Action in diabetes and vascular disease" (ADVANCE) project involves 20 countries from around the world, 12 of them from the EU. The results were presented at the European Society of Cardiology Congress in Vienna, Austria, on 3 September.

A total of 11,140 patients took part in trials, which lasted over four years. Half of the participants received a fixed combination of two blood pressure-lowering drugs (perindopril and indapamide) in a single tablet, daily. The other half received a matching inactive placebo.

"These results represent an important step forward in health care for millions of people with diabetes worldwide," said Professor Stephen MacMahon from the George Institute for International Health in Australia. "This treatment reduced the likelihood of dying from the complications of diabetes by almost one-fifth, with virtually no side-effects."

Type 2 diabetes is the most common form of diabetes, mostly affecting adults. Sufferers are known to be at a high risk of developing major health problems earlier in life than those without diabetes. In particular, sufferers are more likely to experience a heart attack, stroke, blindness, kidney failure and leg ulcers that can lead to amputation.

The study participants were already receiving most of the standard treatments for diabetes, including other drugs to lower blood pressure. But the precise combination used in this study resulted in a 14% reduction in the risk of death, and an 18% reduction in the risk of death from cardiovascular disease. "In absolute terms, one death would be avoided for every 79 patients treated with the fixed combination of perindopril and indapamide for five years," said Study Director Dr Anushka Patel, also from the George Institute.

Currently around 250 million people worldwide have diabetes, and this number is growing rapidly. The majority of these people will either die or become disabled by the complications inherent in their condition.

For further information, please visit:
http://www.advance-trial.com/static/html/prehome/prehome.asp

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...

Researchers urge clinical trial of blood pressure …

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially r...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Official COVID-19 deaths underestimate the full im…

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December...

Local climate unlikely to drive the early COVID-19…

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal ...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

AstraZeneca advances response to global COVID-19 c…

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations...

Antibody neutralizes SARS and COVID-19 coronavirus…

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the c...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...